Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Christian Chabannon1, Jérôme Larghero2

  • 1Institut Paoli-Calmettes, Centre de Thérapie Cellulaire & Inserm CBT-1409, Centre d'Investigations Cliniques en Biothérapies de Marseille, 13009 Marseille, France.

Bulletin Du Cancer
|January 29, 2019
PubMed
Summary

French healthcare providers face challenges in organizing CAR-T cell therapy delivery and manufacturing. Adapting to complex regulations is key to improving patient access to these innovative treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients.

Bone marrow transplantation·2026
Same author

Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.

Frontiers in oncology·2026
Same author

Equivalent CD34+ selection outcomes with CliniMACS prodigy and CliniMACS plus, enabling cryopreserved product processing.

Cytotherapy·2026
Same author

Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Bone marrow transplantation·2026
Same author

Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.

Leukemia·2026
Same author

Biointegration of a partially decellularized tracheal scaffold in a porcine model - preliminary results.

Scientific reports·2026

Area of Science:

  • Oncology
  • Immunotherapy
  • Regulatory Science

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapies show promise for CD19+ lymphoid malignancies.
  • Limited access to CAR-T cell therapy in European and French hospitals persists.
  • Regulatory compliance for Advanced Therapy Medicinal Products (ATMPs) presents a significant hurdle.

Purpose of the Study:

  • To review the organizational framework for CAR-T cell therapy in France.
  • To identify requirements for manufacturing and delivery of CAR-T cells.
  • To address challenges in accessing innovative cell-based medicinal products.

Main Methods:

  • Review of European and French regulations for ATMPs.
  • Analysis of organizational requirements for industry-manufactured CAR-T cells.
Keywords:
Acute leukemiaCAR-t cellsCell therapiesImmunotherapieImmunotherapyLeucémie aigueLymphomaLymphomeRegulationRéglementationThérapies cellulaires

Related Experiment Videos

  • Examination of frameworks for CAR-T cells produced for clinical research.

    • Main Results:

    • Establishing a compliant organizational structure is crucial for CAR-T cell therapy implementation.
    • Two distinct organizational models are discussed: industry-manufactured and investigational CAR-T cells.
    • Regulatory compliance is a primary factor influencing treatment accessibility.

    Conclusions:

    • French healthcare systems need to adapt organizational structures to meet CAR-T cell therapy demands.
    • Streamlining regulatory pathways can improve patient access to CAR-T cell treatments.
    • Further development of organizational frameworks is essential for advancing cell-based therapies.